Erasca (ERAS) Cash from Operations (2020 - 2026)
Erasca (ERAS) reported Cash from Operations of 27383000.0 for Q1 2026, up 13.22% on a YoY basis from 24185365.83 in Q1 2025, and down 26.13% quarter-over-quarter from 21711000.0 in Q4 2025.
Erasca (ERAS) Cash from Operations (2020 - 2026) Analysis & Trends
Erasca has reported Cash from Operations for 7 years, with the latest figure at 27383000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 13.22% year-over-year to 27383000.0; the trailing twelve-month figure through Mar 2026 stood at 91283000.0 (up 15.26% YoY), and the FY2025 full-year result was 95455000.0, up 12.76% from the prior year.
- Cash from Operations for Q1 2026 stood at 27383000.0, down from 21711000.0 in the prior quarter.
- The five-year high for Cash from Operations was 20531000.0 in Q2 2025, with the low at 33251000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 25690352.94 across 5 years, with a median of 25806000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 64.73% — and 2025, when it increased 29.65%.
- Erasca's Cash from Operations stood at 26372000.0 in 2022, then grew by 6.01% to 24788000.0 in 2023, then grew by 0.9% to 24564000.0 in 2024, then increased by 11.61% to 21711000.0 in 2025, then decreased by 26.13% to 27383000.0 in 2026.
- The last three Cash from Operations figures came in at 27383000.0 (Q1 2026), 21711000.0 (Q4 2025), and 21658000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | -27.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.38 Mn |
| Mar 31, 2026 | -27.38 Mn |
| Dec 31, 2025 | -21.71 Mn |
| Dec 31, 2025 | -21.71 Mn |
| Sep 30, 2025 | -21.66 Mn |
| Sep 30, 2025 | -21.66 Mn |
| Jun 30, 2025 | -20.53 Mn |
| Jun 30, 2025 | -20.53 Mn |
| Mar 31, 2025 | -31.56 Mn |
| Mar 31, 2025 | -31.56 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Sep 30, 2024 | -22.42 Mn |
| Sep 30, 2024 | -22.42 Mn |
| Jun 30, 2024 | -29.18 Mn |
| Jun 30, 2024 | -29.18 Mn |
| Mar 31, 2024 | -33.25 Mn |
| Mar 31, 2024 | -33.25 Mn |
| Dec 31, 2023 | -24.79 Mn |
| Dec 31, 2023 | -24.79 Mn |